Anti-ANGPTL3 antibody SHR-1918 (600 mg every 4 weeks) was associated with ~59% LDL-C reduction and manageable safety profile in adults with homozygous familial hypercholesterolemia on stable lipid-lowering therapy - Vera Health 뉴스